/
AMR
ANTIMICROBIAL RESISTANCE

Why?

Antimicrobial resistance (AMR) is a global health and development threat.

It requires urgent action in order to achieve the Sustainable Development Goals (SDGs). The World Health Organization has declared that AMR is one of the top 10 global public health threats facing humanity. – source: (WHO Nov 2021)

What is AMR?

Antimicrobial Resistance (AMR) occurs when microorganisms eg. bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become increasingly difficult or impossible to treat. ( WHO 2021.)

More than 1.2 million people – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections, according to the most comprehensive estimate to date of the global impact of antimicrobial resistance (AMR). (Source: ©University of Oxford 2022)

Current situation

Today more and more infections do not respond to drug treatment and life-saving medical procedures are becoming much riskier due to the threat of untreatable infections. The selective pressure created by the broad use of antibiotics many life aspects lead to the expansion of multidrug resistant organisms (MDROs) on a global level. Addressing the rising threat of AMR requires therefore a multidisciplinary approach. One Health Strategy integrates human, veterinary, but also environmental, aquatic, and wildlife issues into current approaches.

AMR is a global crisis. There is no time to wait.

Therefore, Biomedica provides a comprehensive product portfolio in the field of Antimicrobial Resistance.

MICRONAUT antimicrobial susceptibility testing by Merlin/Bruker The test principle of the MICRONAUT system for antimicrobial susceptibility testing (AST) is based on phenotypic detection of resistance as expressed by microbial growth in presence of antibiotic compounds. This micro dilution procedure is a standardized method and a worldwide accepted reference system for determination of the minimal inhibitory concentration (MIC).

Products

MICRONAUT-S
Microplates for automated or manual susceptibility testing of bacteria

UMIC® product line
High accuracy single drug MIC testing

MICRONAUT-AM
MIC plates for the automated or manual susceptibility testing of yeast

MICRONAUT-UR
System for bacteriological diagnostics in urinary tract infection (UTI)


Gradientech QuickMIC® Ultra-rapid antibiotic susceptibility testing
QuickMIC is designed to strengthen your lab by providing reliable and precise results at outstanding speed.

  • Precise MIC values in 2-4 hours
  • Direct from positive blood cultures
  • Antibiotic panels for G+ and G- bacteria


Panels
QuickMIC GN
For Gram-negative bacteria: E.coli, Klebsiella spp., P. aeruginosa, E. cloacae, A. baumannii, P. mirabilis, C. koseri, S. marcescens.

QuickMIC GP
For Gram-positive bacteria: S. aureus, E. faecalis, E. faecium.

Besides a wide variety of ATCC® strains with different resistance properties in the convenient KWIK-STIK™ format our partner Microbiologics also offers a comprehensive portfolio of inactivated or synthetic standards for the quality control of your molecular testing system.

T2 Resistance Panel

The T2 Resistance Panel is the first direct-from-blood detection of resistance markers: The T2Resistance® Panel is designed for the direct-from-blood detection of antibiotic resistance genes associated with sepsis-causing pathogens. In 2019, the FDA granted “Breakthrough Device” designation for the T2Resistance Panel, reflecting the purpose of the panel to rapidly identify resistant infections.

NG Biotech provides RAPID diagnostic tests for the easy, fast, accurate detection of expressed Mechanisms of Resistance to Antibiotics (AMR) in (multi) drug-resistant bacteria (MDR). All tests are validated at the French National Reference Center on Antimicrobial Resistance (AMR).

NG-Test® CARBA- 5 is a multiplex lateral flow immunoassay for the rapid detection and differentiation of KPC, OXA-48, VIM, IMP and NDM in less than 15 minutes

NG-Test® Blood culture prep allows the Rapid and Direct detection of the major groups of carbapenemases from positive blood culture samples in CPE bacteria using the NG Rapid Test CARBA-5 .

NG-Test® CTX-M Multi is a multiplex lateral flow immunoassay for the rapid detection of the 5 most prevalent ESBL CTX-M Groups (1, 2, 8, 9 and 25) in less than 15 minutes

NG-Test® MCR-1 is a qualitative lateral flow immunoassay for the rapid detection of colistine resistance, in less than 15 minutes.

NG Biotech develops multiplex rapid tests in lateral flow format based on the use of specific monoclonal antibodies.
All tests are validated at the French National Reference Center on Antimicrobial Resistance (AMR).

  • Rapid detection of group 1 CTX-M β-lactamases (ESBL)
    NG-Test CTX-M
  • Detection of CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25 (the main CTX-M groups) with a high negative predictive value – ideal for screening
    NG-Test CTX-M MULTI
  • Rapid detection and differentiation of KPC, OXA, VIM, IMP and NDM
    NG-Test CARBA5
  • Rapid and visual immunoassay for the detection of MCR-1 mediated colistin resistance
    NG-Test MCR-1

Complete Overview: Please Click

10/11/2021